Immunosupperssion in kidney transplantation

被引:5
作者
Legendre, C. [1 ]
Zuber, J. [1 ]
Anglicheau, D. [1 ]
Le Quintrec, M. [1 ]
Martinez, F. [1 ]
Mamzer-Bruneel, M. -F. [1 ]
Thervet, E. [1 ]
机构
[1] Hop Necker Enfants Malad, Serv Transplantat Renale Adulte, F-75015 Paris, France
关键词
kidney transplantation; immunosuppression; anti-calcineurins; mTOR-inhibitors; Mycophenolate mofetil;
D O I
10.1016/j.anuro.2007.08.006
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Kidney transplantation has become the treatment of choice in end-stage chronic renal failure since it significantly improves both the quality of life and the life duration of affected patients, when compared with dialysis. Some of these better results that were observed over the last thirty years are obviously due to significant improvements in the quality of immunosuppression. In the first part of this chapter, the allo-immune response is schematically described regarding the various signals. Then, the mechanisms of action of the available or future immunosuppressive therapies are described in the same order as the alloimmune response. In the third part, the various combinations of immunosuppressive regimens are presented from a historical perspective, outlining not only the positive aspects of each class of drugs but also their side effects and consequences on the practical use of immunosuppression over time. Finally, a brief review of current and future perspectives regarding the improvement of both efficacy and tolerability of immunosuppression in kidney transplantation is presented. (c) 2007 Elsevier Masson SAS. Tous droits reserves.
引用
收藏
页码:276 / 284
页数:9
相关论文
共 47 条
[41]   Immunosuppression minimization: Current and future trends in transplant immunosuppression [J].
Vincenti, F .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (07) :1940-1948
[42]   Costimulation blockade with belatacept in renal transplantation [J].
Vincenti, F ;
Larsen, C ;
Durrbach, A ;
Wekerle, T ;
Nashan, B ;
Blancho, G ;
Lang, P ;
Grinyo, J ;
Halloran, PF ;
Solez, K ;
Hagerty, D ;
Levy, E ;
Zhou, WJ ;
Natarajan, K ;
Charpentier, B .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (08) :770-781
[43]   Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients [J].
Webster, A. ;
Pankhurst, T. ;
Rinaldi, F. ;
Chapman, Jr. ;
Craig, J. C. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (02)
[44]   Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data [J].
Webster, AC ;
Woodroffe, RC ;
Taylor, RS ;
Chapman, JR ;
Craig, JC .
BMJ-BRITISH MEDICAL JOURNAL, 2005, 331 (7520) :810-+
[45]   Target of rapamycin inhibitors (Sirolimus and Everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials [J].
Webster, Angela C. ;
Lee, Vincent W. S. ;
Chapman, Jeremy R. ;
Craig, Jonathan C. .
TRANSPLANTATION, 2006, 81 (09) :1234-1248
[46]   Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. [J].
Wolfe, RA ;
Ashby, VB ;
Milford, EL ;
Ojo, AO ;
Ettenger, RE ;
Agodoa, LYC ;
Held, PJ ;
Port, FK .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (23) :1725-1730
[47]   Immunosuppression and immune monitoring after renal transplantation [J].
Zand, MS .
SEMINARS IN DIALYSIS, 2005, 18 (06) :511-519